US Bancorp
ALLO icon

US Bancorp’s Allogene Therapeutics ALLO Stock Holding History

US Bancorp’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01K Sell
486
-86
-15% -$189 ﹤0.01% 3976
2026
Q1 		$1.4K Buy
+572
New +$1.15K ﹤0.01% 3878
2025
Q3 		– Sell
-184
Closed -$208 – 4007
2025
Q2 		$208 Sell
184
-6,784
-97% -$9.02K ﹤0.01% 4076
2025
Q1 		$10.2K Buy
6,968
+6,229
+843% +$11.7K ﹤0.01% 3429
2024
Q4 		$1.57K Sell
739
-1,043
-59% -$2.57K ﹤0.01% 3898
2024
Q3 		$4.99K Buy
1,782
+212
+14% +$565 ﹤0.01% 3568
2024
Q2 		$3.66K Sell
1,570
-1,813
-54% -$5.35K ﹤0.01% 3597
2024
Q1 		$15.1K Hold
3,383
– – ﹤0.01% 3194
2023
Q4 		$10.9K Buy
3,383
+826
+32% +$2.34K ﹤0.01% 3299
2023
Q3 		$8.11K Buy
2,557
+859
+51% +$3.76K ﹤0.01% 3250
2023
Q2 		$8.44K Buy
1,698
+1,210
+248% +$6.54K ﹤0.01% 3323
2023
Q1 		$2.41K Sell
488
-2,842
-85% -$18.2K ﹤0.01% 3711
2022
Q4 		$20.9K Sell
3,330
-1,593
-32% -$14.7K ﹤0.01% 2973
2022
Q3 		$54K Sell
4,923
-551
-10% -$7.49K ﹤0.01% 2483
2022
Q2 		$63K Buy
5,474
+1,616
+42% +$14.3K ﹤0.01% 2463
2022
Q1 		$35K Buy
3,858
+1,010
+35% +$10.5K ﹤0.01% 2790
2021
Q4 		$42K Buy
2,848
+2,301
+421% +$40.6K ﹤0.01% 2737
2021
Q3 		$14K Sell
547
-9,863
-95% -$234K ﹤0.01% 3285
2021
Q2 		$271K Buy
10,410
+42
+0.4% +$1.2K ﹤0.01% 1846
2021
Q1 		$366K Buy
10,368
+10,071
+3,391% +$340K ﹤0.01% 1654
2020
Q4 		$7K Buy
297
+247
+494% +$8.05K ﹤0.01% 3292
2020
Q3 		$2K Sell
50
-23
-32% -$867 ﹤0.01% 3468
2020
Q2 		$3K Buy
73
+23
+46% +$832 ﹤0.01% 3415
2020
Q1 		$1K Hold
50
– – ﹤0.01% 3533
2019
Q4 		$1K Hold
50
– – ﹤0.01% 3541
2019
Q3 		$1K Buy
+50
New +$1.42K ﹤0.01% 3470

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

US Bancorp's ALLO Position: Q2 2026 in Review

US Bancorp reduced its Allogene Therapeutics (ALLO) stake by 15% in Q2 2026, selling an estimated $189 and leaving 486 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #3976.

US Bancorp first reported a position in ALLO in Q3 2019 and has held it in 26 quarters since. The position peaked at $366K in Q1 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • US Bancorp held 486 shares of Allogene Therapeutics worth $1.01K as of Q2 2026.
  • US Bancorp sold 86 Allogene Therapeutics shares in Q2 2026, an estimated $189.
  • Allogene Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3976 holding.
  • US Bancorp first reported a position in Allogene Therapeutics in Q3 2019 and has held it in 26 quarters since.
  • US Bancorp's Allogene Therapeutics position peaked at $366K in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.